STAT3 and cancer: As a result, blockade of STAT3 appears to be an attractive target for cancer therapy, especially as it is activated by a number of upstream tyrosine kinases, including EGFR and FGFR1, and thereby serves as a central integration point for multiple oncogenic signaling pathways controlling cell cycle, apoptosis, angiogenesis, tumor invasion, and metastasis 10,11.